GET TO KNOW OTHERS IMPACTED BY PLGD-1
Look into these support groups to learn more about PLGD-1, find disease specialists, and access resources for both people living with PLGD-1 and their caregivers.
RYPLAZIM® (plasminogen, human-tvmh) is a medicine used for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia).
RYPLAZIM is contraindicated in patients with known hypersensitivity to plasminogen or other components of RYPLAZIM.
You are encouraged to report negative side effects of prescription drugs to the FDA. Call 1-800-FDA-1088 or www.fda.gov/medwatch.
For more details, please see full Prescribing Information and the Patient Information.
This site is intended for residents of the US only.